Opiant Pharmaceuticals (Nasdaq:OPNT) - Aktienkurs, Nachrichten und Analyse

OPNT Aktienübersicht

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose.

OPNT grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

91.8% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 62.58% pro Jahr

Risikoanalyse

Signifikante Insiderverkäufe in den letzten 3 Monaten

Die Aktionäre wurden im vergangenen Jahr verwässert

Opiant Pharmaceuticals, Inc. Wettbewerber

Amylyx Pharmaceuticals

NasdaqGS:AMLX

US$121.1m

MediWound

NasdaqGM:MDWD

US$125.0m

BioStem Technologies

OTCPK:BSEM

US$136.3m

Assertio Holdings

NasdaqCM:ASRT

US$109.4m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Opiant Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	US$20.65
52-Wochen-Hoch	US$28.15
52-Wochen-Tief	US$7.34
Beta	0.83
11 Monat Veränderung	3.10%
3 Monate Veränderung	2.38%
1 Jahr Veränderung	-22.31%
33 Jahre Veränderung	70.80%
5 Jahre Veränderung	1.77%
Veränderung seit IPO	-82.79%

Aktuelle Nachrichten und Updates

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

Aktionärsrenditen

	OPNT	US Pharmaceuticals	US Markt
7D	-1.3%	1.9%	-0.5%
1Y	-22.3%	20.3%	24.2%

Rendite im Vergleich zur Industrie: OPNT unter dem Niveau der Branche US Pharmaceuticals, die im vergangenen Jahr eine Rendite von 18.6% erzielte.

Rendite vs. Markt: OPNT hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is OPNT's price volatile compared to industry and market?
OPNT volatility
OPNT Average Weekly Movement	1.5%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: OPNT hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: OPNTDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 19% auf 1% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2005	38	Roger Crystal	www.opiant.com

Opiant Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Opiant Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
OPNT grundlegende Statistiken
Marktanteil	US$108.80m
Gewinn(TTM)	-US$33.09m
Umsatz(TTM)	US$22.34m

4.9x

Kurs-Umsatz-Verhältnis

-3.3x

Kurs-Gewinn-Verhältnis

Ist OPNT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
OPNT Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$22.34m
Kosten der Einnahmen	US$29.45m
Bruttogewinn	-US$7.11m
Sonstige Ausgaben	US$25.97m
Umsatz	-US$33.09m

Zuletzt gemeldete Gewinne

Sep 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-6.28
Bruttomarge	-31.85%
Nettogewinnspanne	-148.12%
Schulden/Eigenkapital-Verhältnis	67.1%

Wie hat sich OPNT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

OPNT Aktienübersicht

Belohnungen

Risikoanalyse

Opiant Pharmaceuticals, Inc. Wettbewerber

NasdaqGS:AMLX

US$121.1m

NasdaqGM:MDWD

US$125.0m

OTCPK:BSEM

US$136.3m

NasdaqCM:ASRT

US$109.4m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

President recently sold US$102k worth of stock

Consensus revenue estimates increase by 15%

Price target decreased to US$21.50

Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

Consensus revenue estimates fall by 45%

Recent updates

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

President recently sold US$102k worth of stock

Consensus revenue estimates increase by 15%

Price target decreased to US$21.50

Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

Consensus revenue estimates fall by 45%

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Insufficient new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Opiant Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Opiant Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering Opnt004 for the Treatment of Cannabinoid Hyperemesis Syndrome

Consensus revenue estimates fall by 13%

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Opiant Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Opiant Pharmaceuticals, Inc. announced that it expects to receive $2.1 million in funding from AptarGroup, Inc., Valois SAS

Independent Director recently sold US$275k worth of stock

Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

Independent Chairman recently bought US$368k worth of stock

Consensus EPS estimates fall by 47%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Opiant Pharmaceuticals, Inc. Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone

Insufficient new directors

Opiant Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Investor sentiment improved over the past week

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

President recently sold US$52k worth of stock

Opiant Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Trial of Opnt002

Investor sentiment deteriorated over the past week

Insufficient new directors

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Investor sentiment deteriorated over the past week

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS US$0.77 (vs US$0.17 in 3Q 2020)

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Independent Chairman recently bought US$174k worth of stock

Independent Director exercised options and sold US$1.6m worth of stock

Second quarter 2021 earnings released: EPS US$0.39 (vs US$0.051 loss in 2Q 2020)

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Consensus revenue estimates increase to US$37.0m

Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from Russell 3000E Value Index

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.40 loss in 1Q 2020)

Opiant Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2021

Independent Director exercised options to buy US$101k worth of stock.

Analysts update estimates

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.89 profit in FY 2019)

Revenue and earnings beat expectations

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021

Independent Director exercised options to buy US$97k worth of stock.

Erträge & Einnahmen